Technology
-
Iksuda Therapeutics Deepens Clinical Pipeline Through Licensing Agreement for Her2 Antibody Drug Conjugate Programme From LegoChem Biosciences
US phase 1 study expected to begin H1 2022; asset generated impressive preclinical results, <br … Business Wire India US phase 1 study expected to begin H1 2022; asset generated impressive preclinical results, Global (excluding…
Read More »